- Home
- IGMS vs TLSA Comparison
IGMS vs TLSA Comparison
Compare IGMS & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- TLSA
- Stock Information
- Founded
- IGMS 1993
- TLSA 2013
- Country
- IGMS United States
- TLSA United Kingdom
- Employees
- IGMS N/A
- TLSA N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- IGMS Health Care
- TLSA Health Care
- Exchange
- IGMS Nasdaq
- TLSA Nasdaq
- Market Cap
- IGMS 82.1M
- TLSA 87.8M
- IPO Year
- IGMS 2019
- TLSA 2000
- Fundamental
- Price
- IGMS $1.22
- TLSA $1.07
- Analyst Decision
- IGMS Hold
- TLSA
- Analyst Count
- IGMS 8
- TLSA 0
- Target Price
- IGMS $6.14
- TLSA N/A
- AVG Volume (30 Days)
- IGMS 167.6K
- TLSA 363.4K
- Earning Date
- IGMS 05-07-2025
- TLSA 05-09-2025
- Dividend Yield
- IGMS N/A
- TLSA N/A
- EPS Growth
- IGMS N/A
- TLSA N/A
- EPS
- IGMS N/A
- TLSA N/A
- Revenue
- IGMS $2,679,000.00
- TLSA N/A
- Revenue This Year
- IGMS $121.76
- TLSA N/A
- Revenue Next Year
- IGMS $46.83
- TLSA N/A
- P/E Ratio
- IGMS N/A
- TLSA N/A
- Revenue Growth
- IGMS 25.77
- TLSA N/A
- 52 Week Low
- IGMS $0.92
- TLSA $0.49
- 52 Week High
- IGMS $22.50
- TLSA $1.91
- Technical
- Relative Strength Index (RSI)
- IGMS 47.65
- TLSA 53.21
- Support Level
- IGMS $1.16
- TLSA $0.76
- Resistance Level
- IGMS $1.31
- TLSA $1.13
- Average True Range (ATR)
- IGMS 0.12
- TLSA 0.11
- MACD
- IGMS 0.03
- TLSA -0.00
- Stochastic Oscillator
- IGMS 76.92
- TLSA 85.00
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.